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OBJECTIVES: A general societal preference for prioritizing treatment of rare diseases 
over common ones could provide a justiﬁ cation for accepting higher cost-effectiveness 
thresholds for orphan drugs. We attempt to determine whether such a preference 
exists. METHODS: We surveyed a random sample of 1547 Norwegians aged 40–67. 
Respondents chose between funding treatment for a rare versus common disease and 
completed a person trade-off (PTO) exercise between the diseases for each of two 
scenarios: 1) identical per person costs, and 2) higher costs for the rare disease. Dis-
eases were described identically with the exception of prevalence. Respondents were 
randomized to either no information or different amounts of information about 
disease severity (severe vs. moderate) and expected beneﬁ ts of treatment (high vs. low). 
All respondents rated ﬁ ve statements concerning equity attitudes on a Likert-scale. 
RESULTS: A total of 68% of respondents agreed completely with the statement “rare 
disease patients should have equal right to treatment regardless of costs.” Faced with 
trade-offs, 11.3% of respondents favored treating the rare disease, 24.9% the common 
disease and 64.8% expressed indifference. When the rare disease entailed a higher 
opportunity cost, results were 7.4%, 45.3% and 47.3%, respectively. Framing (“extra 
funding” vs. “replace patients”) and amount of information about severity and treat-
ment effectiveness had a small impact on preferences. CONCLUSIONS: Although 
there is strong support for general statements expressing a desire for equal treatment 
rights for rare disease patients, that support evaporates when individuals are faced 
with opportunity costs.
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THE HTA PUZZLE: VALUES, PRIORITIES, TECHNOLOGY 
AFFORDABILITY, AND PATIENT AND COMMUNITY PREFERENCES. 
HOW CAN WE MAKE IT LL FIT TOGETHER?
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OBJECTIVES: This research considers how mature health technology assessment 
(HTA) systems incorporate patient and community preferences and priorities into 
decision-making processes. This presentation examines the policy rationale for 
increased patient and community involvement, as well as providing case studies to 
illustrate different approaches to community focused HTA practices. Effective options 
for patient and community engagement will also be covered. METHODS: Qualitative 
semi-structured interviews with key stakeholders in six developed countries: Australia, 
Canada, England, France, Germany, and Scotland. a literature review was also under-
taken to assess current HTA systems across the six countries. RESULTS: There was 
signiﬁ cant variation across countries in terms of implementation, organization, and 
prioritization. This study revealed two different, but parallel, considerations that are 
important in HTAs: The ‘consumer perspective’ offers insight into variations in health 
outcomes of technologies being assessed, as well as providing detail beyond what is 
captured by QALY assessments in relation to community values, preferences, and 
priorities. Secondly, the ‘community perspective’ takes a broader societal approach to 
examine values, access, use, affordability of new technologies. CONCLUSIONS: An 
understanding of these two ‘HTA puzzle pieces’ is required for the establishment of 
governance and participation processes that will enable well deﬁ ned consumer and 
community roles in HTA, and will lead to more systematic approaches to the integra-
tion of patient perspectives. Findings from this research suggest there is a strong need 
to consider a wider perspective of patient engagement in health policy and delivery, 
of which HTA is but one part.
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OBJECTIVES: Research was undertaken to determine the impact and value of solicit-
ing patient viewpoints at key stages within the drug development lifecycle. METHODS: 
Interviews were held with representatives from the biopharmaceutical, regulatory and 
pricing and reimbursement sectors to identify the value and impact attributed to 
patient perspectives. Additionally, surveys of European patient organizations and 
patients with airways disease provided insight into their attempts to inﬂ uence treat-
ment decisions, which could affect market uptake. RESULTS: Industry ngagement 
with patients was often reactive and linked to the identiﬁ cation of factors which may 
impact on the success of a product. Earlier consultation may help the biopharmaceuti-
cal industry to optimise product development or assist key go/no-go decisions. Whilst 
there is a harmonised regulatory process that engages patient organizations through 
the European Medicines Agency, patient viewpoints or quality of life data seldom 
inﬂ uence access or pricing and reimbursement decisions in the main European 
markets. Numerous examples were cited where this has led to political lobbying and 
emotive decision making and a more transparent process involving patients may help 
to ensure decisions are based on clinical and cost-effectiveness. Involving patients in 
the drug development lifecycle has the potential to improve health outcomes and 
reduce health expenditure associated with poor management, often related to non-
compliance. The earlier patients are involved, the greater the potential to avert or 
minimise factors that could affect commercial success and return on investment. 
CONCLUSIONS: For the biopharmaceutical industry, the value of patient perspec-
tives lies as part of a risk-mitigation strategy to provide greater insight and control 
over factors that affect market success. For regulators and payers, the value lies in the 
potential to improve health outcomes and reduce health care budgets.
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OBJECTIVES: In March 2010, President Barak Obama signed the Patient Protection 
and Affordable Care Act (PPACA), which radically changed the health care landscape 
in the United States. We carried out a survey to gauge consumers’ opinion about the 
U.S. health care system after the PPACA was signed into the U.S. law. METHODS: 
We commissioned Harris Interactive to conduct a nationally representative telephone 
survey of 1,019 adults from the U.S. between May 21–24. Respondents were ques-
tioned on their current insurance coverage status, their knowledge about the PPACA, 
and their perception of the reform. Data were weighted to be representative of the 
total U.S. adult population in terms of age, sex, geographic region and race. The survey 
has a sampling error of ±3% at 95% conﬁ dence level. RESULTS: 84% of all adults 
surveyed have an health insurance; 96% of adults 65 years old and above have health 
insurance. Overall, while 36% of all adults surveyed think they will be “better off” 
as a result of the reform; 43% think they will become “worse off”. 61% of respon-
dents said they are “very knowledgeable” or “somewhat knowledgeable” about the 
PPACA; 54% of adults surveyed who rated themselves as “very knowledgeable” think 
they will be “worse off” as a result of the bill. Adults surveyed anticipate an increase 
in tax (76%), hospital and physician prices (65%), health insurance cost (65%) and 
cost of medications (54%). CONCLUSIONS: According to the survey, while the 
majority of consumers are satisﬁ ed with their current health care coverage, many have 
concerns about potential changes from PPACA. Concerns include health insurance 
coverage, access to quality health care and potential cost increase. In addition, the 
majority of consumers said that they are at least somewhat knowledgeable about 
PPACA. 
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OBJECTIVES: In our earlier study we found that measured by the number of cases 
(patients), the market share of intensive therapy was analyzed in Hungary and was 
found between 0.84% and 1.80% during a 14-year period (1995–2008). The dis-
charge of patient not needing intensive therapy is obligated. The aim of the study was 
to analyze patient discharge. METHODS: Data were derived from the National 
Health Insurance Fund Administration. The two types of patient discharge were 
analyzed during a 9-year period, the discharges from intensive care unit within the 
same hospital and between different hospitals from 2000 to 2008. RESULTS: Com-
pared to the total discharges the within and between hospitals discharges changed 
between 70.6% (2000) and 77.3% (2005) during the 9 years (2000–2008). Within 
hospital discharge started from 65.2% (2000) and the highest value was 73.0% 
(2006). Between hospitals discharged changed between 2.9% (2006) and 5.4% 
(2000). The sum of the two types discharge steadily increased from 70.6% (2000) to 
77.3% (2005) in the ﬁ rst 6 years and after a linear descending it ﬁ nished on 74.7% 
in 2008. Within hospital discharge increased from 65.2% (2000) to 73.0% (2006) 
and decrease to 69.6% until 2008. Between hospitals discharges decreased from 5.4% 
(2000) to 4.3% (2001), but it were steady from 2002 to 2005 (4.5%–4.8%). In 2006 
a sudden decrease happend to 2.9% and after it the values were 3.3%–3.2% in the 
last 2 years. The mean of the within hospital discharges were 70.5% while the between 
hospitals discharges were 4.2%. CONCLUSIONS: In Hungary between 2000 and 
2008 the discharges of the patients from the intensive care units to other hospital 
departments were 70.5%. The majority (94.38%) of the discharged patients was 
treated in the same hospital and only a minor proportion (5.62%) were moved to 
other hospitals. 
